Literature DB >> 19371133

Hydrating for resistance to radicicol.

Adam S Duerfeldt1, Brian S J Blagg.   

Abstract

Resistance to Hsp90 inhibition has become an important concern as several clinical trials are currently in progress for the treatment of cancer. A summary of known mechanisms of resistance to Hsp90 inhibitors is provided, including the recent solution of the Humicola fuscoatra Hsp90 structure, the organism responsible for the biosynthesis of radicicol. Through careful analyses of Hsp90 structures, a plausible mechanism for resistance to Hsp90 inhibitors has been obtained by single mutations about the N-terminal ATP-binding site.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19371133      PMCID： PMC2843399          DOI： 10.1021/cb9000712

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN： 1554-8929            Impact factor:   5.100


  11 in total

Review 1.  Natural products as sources of new drugs over the last 25 years.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2007-02-20       Impact factor: 4.050

Review 2.  Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.

Authors:  Wanping Xu; Len Neckers
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

Review 3.  The Hsp90 molecular chaperone: an open and shut case for treatment.

Authors:  Laurence H Pearl; Chrisostomos Prodromou; Paul Workman
Journal:  Biochem J       Date:  2008-03-15       Impact factor: 3.857

4.  Structural basis of the radicicol resistance displayed by a fungal hsp90.

Authors:  Chrisostomos Prodromou; James M Nuttall; Stefan H Millson; S Mark Roe; Tiow-Suan Sim; Doreen Tan; Paul Workman; Laurence H Pearl; Peter W Piper
Journal:  ACS Chem Biol       Date:  2009-04-17       Impact factor: 5.100

5.  Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.

Authors:  M N Benchekroun; E Schneider; A R Safa; A J Townsend; B K Sinha
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

6.  P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

Authors:  Andrea K McCollum; Cynthia J TenEyck; Bridget Stensgard; Bruce W Morlan; Karla V Ballman; Robert B Jenkins; David O Toft; Charles Erlichman
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

7.  p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity.

Authors:  Fedor Forafonov; Oyetunji A Toogun; Iwona Grad; Elena Suslova; Brian C Freeman; Didier Picard
Journal:  Mol Cell Biol       Date:  2008-03-24       Impact factor: 4.272

8.  SBA1 encodes a yeast hsp90 cochaperone that is homologous to vertebrate p23 proteins.

Authors:  Y Fang; A E Fliss; J Rao; A J Caplan
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

9.  Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.

Authors:  Nathalie Gaspar; Swee Y Sharp; Simon Pacey; Chris Jones; Michael Walton; Gilles Vassal; Suzanne Eccles; Andrew Pearson; Paul Workman
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

10.  Pharmacological and genetic analysis of 90-kDa heat shock isoprotein-aryl hydrocarbon receptor complexes.

Authors:  Marc B Cox; Charles A Miller
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436
View more
  2 in total

Review 1.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  Hsp90 inhibition: elimination of shock and stress.

Authors:  Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2010-07-01       Impact factor: 2.823
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.